273 related articles for article (PubMed ID: 15371980)
1. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.
Giessmann T; May K; Modess C; Wegner D; Hecker U; Zschiesche M; Dazert P; Grube M; Schroeder E; Warzok R; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Sep; 76(3):192-200. PubMed ID: 15371980
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine.
Brueck S; Bruckmueller H; Wegner D; Busch D; Martin P; Oswald S; Cascorbi I; Siegmund W
Mol Pharm; 2019 Sep; 16(9):3823-3830. PubMed ID: 31361500
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
[TBL] [Abstract][Full Text] [Related]
5. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
6. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
7. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas.
Nakamura T; Sakaeda T; Ohmoto N; Tamura T; Aoyama N; Shirakawa T; Kamigaki T; Nakamura T; Kim KI; Kim SR; Kuroda Y; Matsuo M; Kasuga M; Okumura K
Drug Metab Dispos; 2002 Jan; 30(1):4-6. PubMed ID: 11744604
[TBL] [Abstract][Full Text] [Related]
8. Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines.
Li Q; Sai Y; Kato Y; Tamai I; Tsuji A
Pharm Res; 2003 Aug; 20(8):1119-24. PubMed ID: 12948007
[TBL] [Abstract][Full Text] [Related]
9. Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.
Matthaei J; Tzvetkov MV; Gal V; Sachse-Seeboth C; Sehrt D; Hjelmborg JB; Hofmann U; Schwab M; Kerb R; Brockmöller J
Genome Med; 2016 Nov; 8(1):119. PubMed ID: 27825374
[TBL] [Abstract][Full Text] [Related]
10. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
Oswald S; Haenisch S; Fricke C; Sudhop T; Remmler C; Giessmann T; Jedlitschky G; Adam U; Dazert E; Warzok R; Wacke W; Cascorbi I; Kroemer HK; Weitschies W; von Bergmann K; Siegmund W
Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
[TBL] [Abstract][Full Text] [Related]
11. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells.
Fan J; Maeng HJ; Du Y; Kwan D; Pang KS
Eur J Pharm Sci; 2011 Jan; 42(1-2):19-29. PubMed ID: 20955791
[TBL] [Abstract][Full Text] [Related]
12. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
13. Grapefruit juice ingestion significantly reduces talinolol bioavailability.
Schwarz UI; Seemann D; Oertel R; Miehlke S; Kuhlisch E; Fromm MF; Kim RB; Bailey DG; Kirch W
Clin Pharmacol Ther; 2005 Apr; 77(4):291-301. PubMed ID: 15903127
[TBL] [Abstract][Full Text] [Related]
14. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
Arias A; Rigalli JP; Villanueva SS; Ruiz ML; Luquita MG; Perdomo VG; Vore M; Catania VA; Mottino AD
Toxicology; 2014 Jun; 320():46-55. PubMed ID: 24685904
[TBL] [Abstract][Full Text] [Related]
15. Effects of carbamazepine on the P-gp and CYP3A expression correlated with PXR or NF-κB activity in the bEnd.3 cells.
Ke XJ; Cheng YF; Yu N; Di Q
Neurosci Lett; 2019 Jan; 690():48-55. PubMed ID: 30312753
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines.
Pfrunder A; Gutmann H; Beglinger C; Drewe J
J Pharm Pharmacol; 2003 Jan; 55(1):59-66. PubMed ID: 12625868
[TBL] [Abstract][Full Text] [Related]
17. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.
Nakamura T; Sakaeda T; Horinouchi M; Tamura T; Aoyama N; Shirakawa T; Matsuo M; Kasuga M; Okumura K
Clin Pharmacol Ther; 2002 Apr; 71(4):297-303. PubMed ID: 11956513
[TBL] [Abstract][Full Text] [Related]
18. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?
Gutmann H; Poller B; Büter KB; Pfrunder A; Schaffner W; Drewe J
Planta Med; 2006 Jun; 72(8):685-90. PubMed ID: 16755466
[TBL] [Abstract][Full Text] [Related]
19. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
20. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
Siegmund W; Ludwig K; Giessmann T; Dazert P; Schroeder E; Sperker B; Warzok R; Kroemer HK; Cascorbi I
Clin Pharmacol Ther; 2002 Nov; 72(5):572-83. PubMed ID: 12426521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
